Search
for
Sort by
Research 121–150 of 1000+
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
- Disease burden, clinical management and unmet treatment need of patients with moderate to severe alopecia areata; consensus statements, insights, and practices from CERTAAE (Central/Eastern EU, Russia, Türkiye AA experts) Delphi panel
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- A case report of occurrence of severe alopecia areata as post-COVID-19 complication
- Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
- Diagnosis and differential diagnosis of tertiary androgenetic alopecia with severe alopecia areata based on high‐resolution MRI
- Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
- Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
- Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
- Clinical analysis of 83 cases of severe alopecia areata
- Appearance of alopecia areata during treatment with tildrakizumab for severe palmoplantar psoriasis
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Complete hair regrowth in a young male with severe atopic dermatitis and alopecia areata after dupilumab: probably more than a coincidence
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Interest of High-Dose Pulse Corticosteroid Therapy Combined with Methotrexate for Severe Alopecia Areata: A Retrospective Case Series
- A trial of 1% minoxidil used topically for severe alopecia areata
- Combined oral pulse and topical corticosteroid therapy for severe alopecia areata in children: a long-term follow-up study
- A trial of 1% minoxidil used topically for severe alopecia areata.
- Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
- Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- High-dose steroid pulse therapy for the treatment of severe alopecia areata.
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
- Sequential high‐ and low‐dose systemic corticosteroid therapy for severe childhood alopecia areata
- A systematic review on the treatment of pediatric severe alopecia areata by topical immunotherapy or Anthralin (contact sensitization) or low‐level light/laser therapy (LLLT): focus on efficacy, safety, treatment duration, recurrence, and follow‐up based on clinical studies
- Role of Hair Prostheses (Wigs) in Patients with Severe Alopecia Areata
- High‐dose pulsed corticosteroid therapy combined with methotrexate for severe alopecia areata of childhood